People | March 07, 2022
AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Subscribe To Our Newsletter & Stay Updated
